|
|
|
|
This promotional program is sponsored by Paratek Pharmaceuticals, Inc and it is not eligible for continuing medical education credits.
|
|
|
|
|
|
Dear [Full Name],
This is a reminder that you have registered to view a Live Broadcast on re-establishing the utility of tetracyclines for current challenges with antimicrobial resistance. Thank you for your
participation!
Program: Re-Establishing the Utility of
Tetracyclines for Current Challenges
with Antimicrobial Resistance
Date: October 1st
Time: 7PM EDT
To view the broadcast on October 1st, please click here or the button below.
|
|
|
|
|
Kerry Laplante, PharmD, FCCP, FIDSA
Professor of Pharmacy
University of Rhode Island
Kingston, RI
|
|
|
|
Abhay Dhand, MD
Infectious Disease Physician
Westchester, NY
|
|
|
|
In this Live Broadcast, Drs. Laplante and Dhand will:
|
|
|
|
|
Review the historical
background on tetracycline
discovery, emerging resistance,
mechanism of action, and their
spectrum of activity.
|
|
|
|
|
|
|
Explain the pharmacokinetic and pharmacodynamic similarities and differences of tetracyclines.
|
|
|
|
|
|
|
Discuss the clinical data supporting tetracycline use for common bacterial infections.
|
|
|
|
|
|
|
Identify applications for tetracycline-class antibiotics after assessing a patient case.
|
|
|
|
|
|
|
© 2020 Paratek Pharmaceuticals, Inc. All rights reserved.
PARATEK® and the hexagon logo are registered trademarks of
Paratek Pharmaceuticals, Inc.
US-NUA-0372 07/20
|
|
|
|
|
|
|
|
|
|
Contagion® – an MJH Life Sciences™ brand
Copyright 2020 © Intellisphere, LLC
2 Clarke Drive | Suite 100 | Cranbury, NJ | 08512
Preferences | Unsubscribe
|
|
|
